Gottfried Rudofsky
Overview
Explore the profile of Gottfried Rudofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudofsky G, Menzen M, Potier L, Catarig A, Clark A, Priyadarshini P, et al.
Adv Ther
. 2024 Dec;
42(2):788-800.
PMID: 39636564
Introduction: To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice. Methods: This post hoc...
2.
Rudofsky G, Amadid H, Braae U, Catrina S, Kick A, Mandavya K, et al.
Diabetes Ther
. 2024 Nov;
16(1):73-87.
PMID: 39535683
Introduction: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and...
3.
Sarandi E, Krueger-Krasagakis S, Tsoukalas D, Evangelou G, Sifaki M, Kyriakakis M, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334880
Psoriasis is a chronic, immune-mediated skin condition with significant metabolic complications. Although lipid metabolism is linked to its pathogenesis, reliable biomarkers and the impact of modifiable factors remain underexplored. The...
4.
Kick A, MRabet-Bensalah K, Acquistapace F, Amadid H, Ambuhl R, Braae U, et al.
Diabetes Ther
. 2024 Jan;
15(3):623-637.
PMID: 38240875
Introduction: Real-world data provide insight into how medications perform in clinical practice. The PIONEER REAL Switzerland study aimed to understand clinical outcomes with oral semaglutide in adults with type 2...
5.
Hepprich M, Roser P, Stiebitz S, Felix B, Schultes B, Schmitz D, et al.
BMJ Open Diabetes Res Care
. 2023 Nov;
11(6).
PMID: 37949471
Introduction: To evaluate awareness and knowledge of diabetic ketoacidosis (DKA), a common and potentially life-threatening complication in people living with type 1 diabetes (T1D). Research Design And Methods: A survey...
6.
Sarandi E, Krueger-Krasagakis S, Tsoukalas D, Sidiropoulou P, Evangelou G, Sifaki M, et al.
Front Mol Biosci
. 2023 Jul;
10:1201912.
PMID: 37405259
Psoriasis is a common inflammatory disease that affects mainly the skin. However, the moderate to severe forms have been associated with several comorbidities, such as psoriatic arthritis, Crohn's disease, metabolic...
7.
Komminoth M, Donath M, Hepprich M, Schuetz P, Blum C, Mueller B, et al.
PLoS One
. 2023 Apr;
18(4):e0281585.
PMID: 37018188
Background: Despite the widespread use of glucocorticoids in inflammatory and autoimmune disorders, there is uncertainty about the safe cessation of long-term systemic treatment, as data from prospective trials are largely...
8.
Schultes B, Ernst B, Timper K, Puder J, Rudofsky G
Int J Obes (Lond)
. 2023 Feb;
47(5):335-337.
PMID: 36806759
No abstract available.
9.
Schuh A, Ayvaz G, Baldeschi L, Baretic M, Bechtold D, Boschi A, et al.
Br J Ophthalmol
. 2023 Jan;
108(2):294-300.
PMID: 36627174
Background: Graves' orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves' Orbitopathy...
10.
Yale J, Bodholdt U, Catarig A, Catrina S, Clark A, Ekberg N, et al.
BMJ Open Diabetes Res Care
. 2022 Apr;
10(2).
PMID: 35383100
Introduction: This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist...